Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
This study is currently recruiting participants.
Verified by Rockefeller University, October 2007
Sponsored by: Rockefeller University
Information provided by: Rockefeller University
ClinicalTrials.gov Identifier: NCT00327236
  Purpose

The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to understand the relationship between their neurological disease, their cancer, and their immune system.


Condition
Paraneoplastic Syndromes

MedlinePlus related topics: Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes

Further study details as provided by Rockefeller University:

Estimated Enrollment: 9
Detailed Description:

Patients with paraneoplastic neurological disorders (PNDs) provide a unique model for studying tumor immunity and neuronal autoimmunity. We hypothesize that T lymphocyte autoimmune dysfunction is involved in the pathogenesis of the paraneoplastic neurological syndromes, and that killer T cells are involved in the targeting and successful killing of tumor cells in these cancer patients. Furthermore, we postulate that this activity may provide a model for autoimmune brain disease. We will assess the immune responses in PND patients, correlate these with the clinical data (time course of disease, symptoms and signs, disability), and collect and archive clinical data, serum and cells from PND patients for current and future studies into the basic immune system phenomenon present in PND patients.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Neurological disease which is suspected to be paraneoplastic
  • No known active additional malignancy other than non-melanoma skin cancer

Exclusion Criteria:

  • Known central nervous system (CNS) metastasis
  • Known active additional malignancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00327236

Contacts
Contact: Noreen Buckley, NP 212-327-7454

Locations
United States, New York
Rockefeller University Hospital Recruiting
New York, New York, United States, 10021
Contact: Noreen Buckley, NP     212-327-7454     nbuckley@rockefeller.edu    
Principal Investigator: Robert Darnell, MD, PHD            
Sponsors and Collaborators
Rockefeller University
Investigators
Principal Investigator: Robert Darnell, MD, PHD Rockefeller University
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Study ID Numbers: RDA-0148
Study First Received: May 17, 2006
Last Updated: October 15, 2007
ClinicalTrials.gov Identifier: NCT00327236  
Health Authority: United States: Institutional Review Board

Keywords provided by Rockefeller University:
Paraneoplastic Neurologic Syndromes

Study placed in the following topic categories:
Paraneoplastic Syndromes

Additional relevant MeSH terms:
Neoplasms
Pathologic Processes
Disease
Syndrome

ClinicalTrials.gov processed this record on January 14, 2009